Morphine is a strong painkiller used to treat moderate to severe pain, such as pain from cancer, heart attacks, or major injuries. It can also be used to help people breathe easier when they have severe shortness of breath.[2] MS Contin is currently approved and in use across 75 indications[4].[1]
MS Contin is one of 908 small molecule programs targeting Cesarean Section. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
744 competitors in Breast Cancer
MS Contin
Voltaren
Zolymbus
Blenoxane
MS Contin
Spravato
Tricor
Cortef
Acupan
Chantix
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Sep 18, 1984
DURAMORPH PF
NDA NDA018565
Sep 12, 1989
MS CONTIN
NDA NDA019516
Jul 12, 1990
MORPHINE SULFATE (AUTOINJECTOR)
NDA NDA019999
Oct 30, 1992
MORPHINE SULFATE
NDA NDA019917
Oct 30, 1992
MORPHINE SULFATE
NDA NDA019916
Nov 23, 1994
ORAMORPH SR
NDA NDA019977
Jul 3, 1996
MORPHINE SULFATE
NDA NDA020631
Mar 20, 2002
AVINZA
NDA NDA021260
May 18, 2004
DEPODUR
NDA NDA021671
Apr 20, 2007
KADIAN
NDA NDA020616
Mar 17, 2008
MORPHINE SULFATE
NDA NDA022207
Mar 17, 2008
MORPHINE SULFATE
NDA NDA022195
Jun 23, 2011
MORPHINE SULFATE
NDA NDA201517
Nov 14, 2011
MORPHINE SULFATE
NDA NDA202515
Oct 30, 2013
MORPHINE SULFATE
NDA NDA204223
Oct 2, 2015
MORPHABOND ER
NDA NDA206544
Jan 9, 2017
ARYMO ER
NDA NDA208603
Sources
Details